NASDAQ:PODD Insulet (PODD) Stock Price, News & Analysis $267.04 -0.95 (-0.35%) As of 01/14/2025 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About Insulet Stock (NASDAQ:PODD) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Insulet alerts:Sign Up Key Stats Today's Range$262.49▼$271.1350-Day Range$239.30▼$275.7052-Week Range$160.19▼$279.77Volume472,937 shsAverage Volume485,355 shsMarket Capitalization$18.73 billionP/E Ratio45.73Dividend YieldN/APrice Target$272.81Consensus RatingModerate Buy Company OverviewInsulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.Read More… Insulet Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks85th Percentile Overall ScorePODD MarketRank™: Insulet scored higher than 85% of companies evaluated by MarketBeat, and ranked 155th out of 955 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.4 / 5Analyst RatingModerate Buy Consensus RatingInsulet has received a consensus rating of Moderate Buy. The company's average rating score is 2.81, and is based on 13 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageInsulet has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Insulet's stock forecast and price target. Earnings and Valuation3.1 / 5Proj. Earnings Growth21.74% Earnings GrowthEarnings for Insulet are expected to grow by 21.74% in the coming year, from $3.22 to $3.92 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Insulet is 45.73, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 109.47.Price to Earnings Ratio vs. SectorThe P/E ratio of Insulet is 45.73, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 85.82.Price to Earnings Growth RatioInsulet has a PEG Ratio of 4.12. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioInsulet has a P/B Ratio of 25.46. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Insulet's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted3.85% of the outstanding shares of Insulet have been sold short.Short Interest Ratio / Days to CoverInsulet has a short interest ratio ("days to cover") of 5.Change versus previous monthShort interest in Insulet has recently increased by 1.50%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldInsulet does not currently pay a dividend.Dividend GrowthInsulet does not have a long track record of dividend growth. Sustainability and ESG4.9 / 5Environmental Score-1.20 Percentage of Shares Shorted3.85% of the outstanding shares of Insulet have been sold short.Short Interest Ratio / Days to CoverInsulet has a short interest ratio ("days to cover") of 5.Change versus previous monthShort interest in Insulet has recently increased by 1.50%, indicating that investor sentiment is decreasing. News and Social Media2.0 / 5News Sentiment0.63 News SentimentInsulet has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.79 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for Insulet this week, compared to 9 articles on an average week.Search InterestOnly 1 people have searched for PODD on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Insulet to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Insulet insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $252,192.00 in company stock.Percentage Held by InsidersOnly 0.47% of the stock of Insulet is held by insiders.Read more about Insulet's insider trading history. Receive PODD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Insulet and its competitors with MarketBeat's FREE daily newsletter. Email Address PODD Stock News HeadlinesInsulet launches Omnipod 5 in five more countries in EuropeJanuary 14 at 7:04 PM | markets.businessinsider.comInsulet Omnipod 5 insulin system available in five more European countriesJanuary 13 at 9:50 PM | seekingalpha.comLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds for a dollar anymore!January 15, 2025 | StocksToTrade (Ad)Insulet Corp Expands Omnipod 5 Availability Across EuropeJanuary 13 at 7:55 PM | gurufocus.comInsulet Launches Revolutionary Omnipod® 5 in Five More Countries in EuropeJanuary 13 at 4:50 PM | finance.yahoo.comInsulet to Announce Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025January 10, 2025 | gurufocus.comInsulet Corp (PODD) Announces Upcoming Financial Results Release for Q4 and Full Year 2024January 10, 2025 | gurufocus.comInsulet to Announce Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025January 10, 2025 | businesswire.comSee More Headlines PODD Stock Analysis - Frequently Asked Questions How have PODD shares performed this year? Insulet's stock was trading at $261.07 at the beginning of the year. Since then, PODD shares have increased by 2.3% and is now trading at $267.04. View the best growth stocks for 2025 here. How were Insulet's earnings last quarter? Insulet Co. (NASDAQ:PODD) released its earnings results on Thursday, August, 8th. The medical instruments supplier reported $0.55 earnings per share for the quarter, missing the consensus estimate of $0.56 by $0.01. The firm's revenue was up 23.2% on a year-over-year basis. Who are Insulet's major shareholders? Insulet's top institutional investors include Assenagon Asset Management S.A. (0.15%), Ayrshire Capital Management LLC (0.03%), Czech National Bank (0.02%) and Nordea Investment Management AB (0.01%). Insiders that own company stock include Charles Alpuche, Timothy J Scannell, James Hollingshead, Wayde D Mcmillan, Bret Christensen, Mark N Field, Michael P Spears, Lauren Budden, Dan Manea, Prem Singh, Shacey Petrovic and Luciana Borio. View institutional ownership trends. How do I buy shares of Insulet? Shares of PODD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Insulet own? Based on aggregate information from My MarketBeat watchlists, some other companies that Insulet investors own include Predictive Oncology (POAI), JPMorgan Chase & Co. (JPM), Abbott Laboratories (ABT), Ford Motor (F), Bank of America (BAC), Wayfair (W) and Wells Fargo & Company (WFC). Company Calendar Last Earnings8/08/2024Today1/15/2025Next Earnings (Confirmed)2/20/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment Current SymbolNASDAQ:PODD CUSIP45784P10 CIK1145197 Webwww.insulet.com Phone(978) 600-7000Fax978-600-0120Employees3,000Year Founded2000Price Target and Rating Average Stock Price Target$272.81 High Stock Price Target$330.00 Low Stock Price Target$200.00 Potential Upside/Downside+2.2%Consensus RatingModerate Buy Rating Score (0-4)2.81 Research Coverage16 Analysts Profitability EPS (Most Recent Fiscal Year)$5.84 Trailing P/E Ratio45.73 Forward P/E Ratio82.93 P/E Growth4.12Net Income$206.30 million Net Margins21.22% Pretax Margin14.95% Return on Equity27.98% Return on Assets9.16% Debt Debt-to-Equity Ratio1.21 Current Ratio3.68 Quick Ratio2.80 Sales & Book Value Annual Sales$1.98 billion Price / Sales9.44 Cash Flow$3.76 per share Price / Cash Flow70.97 Book Value$10.49 per share Price / Book25.46Miscellaneous Outstanding Shares70,145,000Free Float69,815,000Market Cap$18.73 billion OptionableOptionable Beta1.22 Social Links 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report This page (NASDAQ:PODD) was last updated on 1/15/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAll of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Insulet Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Insulet With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.